查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602816

抗體生產市場：按抗體類型、製程和最終用戶分類 - 2025-2030 年全球預測

Antibody Production Market by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), Process (Downstream Processing, Filtration, Upstream Processing), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗體生產市場價值為179.7億美元，預計到2024年將達到201.6億美元，複合年成長率為12.40%，到2030年將達到407.7億美元。

抗體生產市場涉及用於治療、診斷和研究等各種用途的抗體的生產和精製。慢性病的增加、創新藥物的開發以及對準確診斷工具的需求（其應用範圍從癌症治療到自體免疫疾病）都加劇了對該市場的需求。抗體生產的主要最終用途領域包括生物製藥公司、臨床實驗室和研究機構。關鍵的成長要素包括生技的進步、研發投資的增加以及個人化醫療的進步。例如，人工智慧和機器學習在藥物發現過程中的持續整合正在推動抗體生產的創新和效率。開發抗體治療方法來對抗感染疾病和探索神經退化性疾病，以滿足緊迫的全球健康需求，也存在新的機會。

主要市場統計
基準年[2023] 179.7億美元
預測年份 [2024] 201.6億美元
預測年份 [2030] 407.7億美元
複合年成長率（%） 12.40%

然而，挑戰依然存在，包括抗體生產的複雜性和高成本、監管障礙以及對熟練人員的需求。知識產權問題和競爭性市場壓力使成長更加複雜。供應鏈中斷和嚴格的合規標準也阻礙了市場動力。為了克服這些挑戰，促進學術機構和生技公司之間的合作將促進創新。預計未來將出現技術創新的領域包括增強抗體藥物偶聯物和雙特異性抗體。此外，在傳統治療領域之外探索單株抗體的潛力可以開闢新的市場途徑。

簡而言之，抗體生產市場充滿了由技術進步和醫療需求驅動的成長機會，但為了維持成長，企業必須在人才開拓、簡化生產流程和遵守法規方面進行策略性投資。平衡創新、效率和監管合規性對於有效利用市場潛力至關重要。

市場動態：揭示快速發展的抗體生產市場的關鍵市場洞察

供需的動態交互作用正在改變抗體生產市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 人口中慢性病盛行率上升
    • 對標靶治療和個人化藥物的需求不斷成長
    • 醫療基礎設施現代化和醫療費用上漲
  • 市場限制因素
    • 與抗體生產相關的高成本
  • 市場機會
    • 積極進行研究活動，推出新型植物單株抗體
    • 雙特異性抗體在癌症免疫治療的新用途
  • 市場問題
    • 抗體生產的嚴格法律規範

波特五力：駕馭抗體生產市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解抗體生產市場的外部影響

外部宏觀環境因素在塑造抗體生產市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解抗體生產市場的競爭格局

對抗體生產市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣：抗體生產市場供應商績效評估

FPNV定位矩陣是評估抗體生產市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製抗體生產市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對抗體生產市場進行策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口中慢性病盛行率不斷上升
      • 對標靶治療和個人化醫療的需求不斷成長
      • 醫療基礎設施現代化和醫療費用上漲
    • 抑制因素
      • 與抗體生產相關的高成本
    • 機會
      • 積極的研究活動旨在引入新的植物來源單株抗體
      • 雙特異性抗體在癌症免疫治療的新用途
    • 任務
      • 抗體生產的嚴格法規結構
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 抗體生產市場：按抗體類型

  • 介紹
  • 單株抗體
  • 多株抗體

第7章 抗體生產市場：依製程分類

  • 介紹
  • 下游工藝
    • 層析法樹脂
    • 層析法系統
  • 濾
    • 耗材及配件
    • 過濾系統
  • 上游過程
    • 反應器
    • 消耗品

第8章抗體生產市場：依最終用戶分類

  • 介紹
  • 合約研究組織（CRO）
  • 診斷實驗室
  • 製藥和生物技術公司
  • 研究所和學術中心

第9章 北美和南美抗體生產市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太抗體生產市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東、非洲抗體生產市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Cell Signaling Technology, Inc.
  • Eppendorf AG
  • F. Hoffmann-La Roche Ltd.
  • Fibercell Systems Inc
  • GE HealthCare Technologies Inc.
  • Genmab A/S
  • GenScript BIoTech Corporation
  • Gilead Sciences, Inc.
  • INTEGRA Biosciences AG
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pall Corporation
  • Pfizer Inc.
  • ProteoGenix
  • Sanofi SA
  • Sartorius AG
  • Teva Pharmaceutical Industries Ltd.
  • The Antibody Company
  • Thermo Fisher Scientific Inc.
Product Code: MRR-69324464D0EA

The Antibody Production Market was valued at USD 17.97 billion in 2023, expected to reach USD 20.16 billion in 2024, and is projected to grow at a CAGR of 12.40%, to USD 40.77 billion by 2030.

The antibody production market involves the creation and refinement of antibodies for various applications, including therapeutics, diagnostics, and research. The necessity of this market is underscored by the rising prevalence of chronic diseases, innovative drug development, and the need for precise diagnostic tools, with applications spanning from cancer treatment to autoimmune disorders. Major end-use areas for antibody production include biopharmaceutical companies, clinical laboratories, and research institutions. Key growth factors include advancements in biotechnology, increased R&D investment, and the evolving landscape of personalized medicine. For instance, the ongoing integration of AI and machine learning in drug discovery processes is driving innovation and efficiency in antibody production. Emerging opportunities also exist in developing therapeutic antibodies to tackle infectious diseases and in exploring neurodegenerative conditions, responding to pressing global health needs.

KEY MARKET STATISTICS
Base Year [2023] USD 17.97 billion
Estimated Year [2024] USD 20.16 billion
Forecast Year [2030] USD 40.77 billion
CAGR (%) 12.40%

However, challenges persist, such as the complexity and high cost of antibody production, regulatory hurdles, and the need for skilled personnel. Intellectual property concerns and competitive market pressures further complicate growth. The supply chain disruptions and stringent compliance standards can also hinder market momentum. To navigate these challenges, fostering collaborations between academic institutions and biotechnology firms can expedite innovation. Looking forward, areas ripe for innovation include enhancing antibody-drug conjugates and bispecific antibodies, which promise higher specificity and efficacy in treatments. Additionally, exploring the potential of monoclonal antibodies in non-traditional therapeutic areas can open new market avenues.

In essence, while the antibody production market is ripe with opportunities driven by technological advancements and medical needs, companies must strategically invest in talent development, streamline production processes, and remain adaptable to regulatory changes to sustain growth. Achieving a balanced approach in innovation, efficiency, and regulatory compliance will be imperative for leveraging market potential effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Production Market

The Antibody Production Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases among population
    • Growing demand for targeted therapies and personalized medicines
    • Modernization of healthcare infrastructure and increase in healthcare expenditure
  • Market Restraints
    • High costs associated with antibody production
  • Market Opportunities
    • Robust research activities to introduce novel plant-made monoclonal antibody
    • Emerging applications of bispecific antibodies in cancer immunotherapy
  • Market Challenges
    • Stringent regulatory frameworks for antibody production

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Production Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Production Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Production Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Production Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Production Market

A detailed market share analysis in the Antibody Production Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Production Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Production Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibody Production Market

A strategic analysis of the Antibody Production Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibody Production Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Cell Signaling Technology, Inc., Eppendorf AG, F. Hoffmann-La Roche Ltd., Fibercell Systems Inc, GE HealthCare Technologies Inc., Genmab A/S, GenScript Biotech Corporation, Gilead Sciences, Inc., INTEGRA Biosciences AG, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pall Corporation, Pfizer Inc., ProteoGenix, Sanofi S.A., Sartorius AG, Teva Pharmaceutical Industries Ltd., The Antibody Company, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Production Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Antibody Type, market is studied across Monoclonal Antibodies and Polyclonal Antibodies.
  • Based on Process, market is studied across Downstream Processing, Filtration, and Upstream Processing. The Downstream Processing is further studied across Chromatography Resins and Chromatography Systems. The Filtration is further studied across Consumables & Accessories and Filtration Systms. The Upstream Processing is further studied across Bioreactors and Consumables.
  • Based on End-User, market is studied across Contract Research Organizations (CROs), Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Research Institutes & Academic Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases among population
      • 5.1.1.2. Growing demand for targeted therapies and personalized medicines
      • 5.1.1.3. Modernization of healthcare infrastructure and increase in healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with antibody production
    • 5.1.3. Opportunities
      • 5.1.3.1. Robust research activities to introduce novel plant-made monoclonal antibody
      • 5.1.3.2. Emerging applications of bispecific antibodies in cancer immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory frameworks for antibody production
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibody Production Market, by Antibody Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Polyclonal Antibodies

7. Antibody Production Market, by Process

  • 7.1. Introduction
  • 7.2. Downstream Processing
    • 7.2.1. Chromatography Resins
    • 7.2.2. Chromatography Systems
  • 7.3. Filtration
    • 7.3.1. Consumables & Accessories
    • 7.3.2. Filtration Systms
  • 7.4. Upstream Processing
    • 7.4.1. Bioreactors
    • 7.4.2. Consumables

8. Antibody Production Market, by End-User

  • 8.1. Introduction
  • 8.2. Contract Research Organizations (CROs)
  • 8.3. Diagnostic Laboratories
  • 8.4. Pharmaceutical & Biotechnology Companies
  • 8.5. Research Institutes & Academic Centers

9. Americas Antibody Production Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Production Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Production Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Biogen Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. Cell Signaling Technology, Inc.
  • 7. Eppendorf AG
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Fibercell Systems Inc
  • 10. GE HealthCare Technologies Inc.
  • 11. Genmab A/S
  • 12. GenScript Biotech Corporation
  • 13. Gilead Sciences, Inc.
  • 14. INTEGRA Biosciences AG
  • 15. Merck KGaA
  • 16. Novartis AG
  • 17. Novo Nordisk A/S
  • 18. Pall Corporation
  • 19. Pfizer Inc.
  • 20. ProteoGenix
  • 21. Sanofi S.A.
  • 22. Sartorius AG
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. The Antibody Company
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. ANTIBODY PRODUCTION MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY PRODUCTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY PRODUCTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY PRODUCTION MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY RESINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION SYSTMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 279. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2023